Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors
Biosensors · 30.04.2026 · 16 (5) · 253
DOI: 10.3390/bios16050253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 30.04.2026. Verfasst von Dmitry N Shcherbakov und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia. Hauptthemen laut MEDLINE: SARS-CoV-2, Protease Inhibitors, Coronavirus 3C Proteases, Luciferases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
A cell-based screening system for viral protease inhibitors was developed using firefly luciferase fragment complementation and validated on the SARS-CoV-2 3CLpro model. The optimal luciferase variant incorporating the VLQSGF proteolytic site (Luc III) retained 88% of its native activity. A critical requirement for system performance was the use of an extended nsp4–nsp6 fragment of the viral polyprotein rather than the mature protease, underscoring the importance of the native context for 3CLpro activity. The bicistronic construct pCAG-Luc-III-IRES-nsp4-6 enables coordinated expression of the reporter and protease, thereby increasing assay reproducibility. IC50 values obtained in this system for nirmatrelvir and GC376 correlated with live-virus assay data but differed significantly from those of a cell-free FRET assay, reflecting the impact of cellular barriers. This approach combines simplicity, a standard substrate, and high reproducibility, making it promising for high-throughput screening in basic laboratory settings and adaptable to other viral proteases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Novosibirsk, Russia.
- Research Institute of Biological Medicine Center for Recombinant Technologies, Altay State University, 656049 Barnaul, Russia.
- N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Academician Lavrent'ev Ave. 9, 630090 Novosibirsk, Russia.
- Synchrotron Radiation Facility, Siberian Circular Photon Source "SKlF" Boreskov Institute Catalysis, Siberian Branch of the Russian Academy of Sciences, Nikolskiy pr-t, 1, Koltsovo, 630559 Novosibirsk, Russia.
ORCID-Profile: Dmitry N Shcherbakov, Natalia V Volkova, Yulia V Meshkova, Maria K Marenina, Sophia S Borisevich, Svetlana V Belenkaya
Förderung
- Russian Science Foundation
Zitieren
APA
Shcherbakov, D. N., Mordvinova, E. D., Trufanov, V. O., Volkova, N. V., Meshkova, Y. V., Marenina, M. K., Zaykovskaya, A. V., Volosnikova, E. A., Borisevich, S. S., & Belenkaya, S. V. (2026). Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors. Biosensors, 16(5), 253. https://doi.org/10.3390/bios16050253
Vancouver
Shcherbakov DN, Mordvinova ED, Trufanov VO, Volkova NV, Meshkova YV, Marenina MK, et al. Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors. Biosensors. 2026;16(5):253. doi:10.3390/bios16050253
BibTeX
@article{Shcherbakov2026,
author = {Shcherbakov, Dmitry N and Mordvinova, Ekaterina D and Trufanov, Vadim O and Volkova, Natalia V and Meshkova, Yulia V and Marenina, Maria K and Zaykovskaya, Anna V and Volosnikova, Ekaterina A and Borisevich, Sophia S and Belenkaya, Svetlana V},
title = {Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors},
journal = {Biosensors},
year = {2026},
volume = {16},
number = {5},
pages = {253},
doi = {10.3390/bios16050253}
}
EUVIMED